来源：新浪证券-红岸工作室 2月27日，君实生物涨0.18%，成交额2.13亿元，换手率0.82%，总市值349.07亿元。 异动分析 猴痘概念+生物疫苗+创新药+AIGC概念 1、公司公众号：2023年10月27日，君实生物宣布，公司与北京大学、中国科学院微生物研究所（中科 院微生物所）、山西高等创新研究院、北京航空航天大学达成合作，共同开发猴痘重组蛋白疫苗。 2、2024年3月12日互动易：公司控股子公司君拓生物通过与科研院所和高校合作开发等形式持有疫苗相 关产品管线，如猴痘疫苗、寨卡疫苗等，目前均处于临床前开发阶段。 3、2024年年报，公司具备完整的从创新药物的发现和开发、 在全球范围内的临床研究、 大规模生产到 商业化的全产业链能力， 旨在成为立足中国、 布局全球的创新医药公司。 公司坚持质量为本、 求真务 实、 诚信合规、 追求卓越的企业价值观， 致力于通过源头创新以及合作开发等形式来研发 first-in-class （同类首创）或 best-in-class（同类最优） 的药物。 通过卓越的创新药物发现能力、 强大的生物技术研 发能力和大规模生产能力， 公司已成功开发出极具市场潜力的药品组合， ...

来源：新浪证券-红岸工作室 2月26日，三态股份涨1.64%，成交额1.83亿元，换手率8.94%，总市值73.44亿元。 异动分析 AIGC概念+AI智能体+多模态AI+跨境电商+人民币贬值受益 主力持仓 1、公司上市保荐书：公司研发项目：A+智能图片生成项目：AIGC项目之一，通过Stable Diffusion生成 高质量图片，利用mask机制控制生成过程中每个像素点的生成概率。通过调整掩膜值，经过训练的模 型可以实现图像生成过程的精细调控，从而可以根据目标生成高质量、多样化的图像。通过文本输入描 述应用场景并添加自有元素，模板化订制自身产品形象，塑造品牌IP，大幅提升运营效率和节约制作成 本。同时，在图片处理环节也引入AI工具，自动生成各种场景图、尺寸图、细节图，极大减少美工和 运营工作量。 2、根据公司官网，2025 年 2 月 20 日，睿观凭借其在技术创新上的敏锐洞察力和前瞻性布局，正式发 布旗下创新力作 —— 对话式跨境侵权违规检测 AI 工具"睿观 AI 助手"。这款工具的问世，为广大跨境 卖家、运营人员以及产品开发者提供了高效、智能的侵权排查全新方案，有望重塑跨境电商合规运营的 新格局。 ...

AIGC概念+AI智能体+多模态AI+跨境电商+人民币贬值受益 2月24日，三态股份涨0.00%，成交额1.31亿元，换手率6.45%，总市值72.89亿元。 异动分析 1、公司上市保荐书：公司研发项目：A+智能图片生成项目：AIGC项目之一，通过Stable Diffusion生成 高质量图片，利用mask机制控制生成过程中每个像素点的生成概率。通过调整掩膜值，经过训练的模 型可以实现图像生成过程的精细调控，从而可以根据目标生成高质量、多样化的图像。通过文本输入描 述应用场景并添加自有元素，模板化订制自身产品形象，塑造品牌IP，大幅提升运营效率和节约制作成 本。同时，在图片处理环节也引入AI工具，自动生成各种场景图、尺寸图、细节图，极大减少美工和 运营工作量。 2、根据公司官网，2025 年 2 月 20 日，睿观凭借其在技术创新上的敏锐洞察力和前瞻性布局，正式发 布旗下创新力作 —— 对话式跨境侵权违规检测 AI 工具"睿观 AI 助手"。这款工具的问世，为广大跨境 卖家、运营人员以及产品开发者提供了高效、智能的侵权排查全新方案，有望重塑跨境电商合规运营的 新格局。 来源：新浪证券-红岸工作室 主力没有控 ...

异动分析 来源：新浪证券-红岸工作室 2月24日，君实生物涨0.00%，成交额2.16亿元，换手率0.82%，总市值351.85亿元。 猴痘概念+生物疫苗+创新药+AIGC概念 1、公司公众号：2023年10月27日，君实生物宣布，公司与北京大学、中国科学院微生物研究所（中科 院微生物所）、山西高等创新研究院、北京航空航天大学达成合作，共同开发猴痘重组蛋白疫苗。 2、2024年3月12日互动易：公司控股子公司君拓生物通过与科研院所和高校合作开发等形式持有疫苗相 关产品管线，如猴痘疫苗、寨卡疫苗等，目前均处于临床前开发阶段。 3、2024年年报，公司具备完整的从创新药物的发现和开发、 在全球范围内的临床研究、 大规模生产到 商业化的全产业链能力， 旨在成为立足中国、 布局全球的创新医药公司。 公司坚持质量为本、 求真务 实、 诚信合规、 追求卓越的企业价值观， 致力于通过源头创新以及合作开发等形式来研发 first-in-class （同类首创）或 best-in-class（同类最优） 的药物。 通过卓越的创新药物发现能力、 强大的生物技术研 发能力和大规模生产能力， 公司已成功开发出极具市场潜力的药品组合， ...

Core Viewpoint - The company, Zhaochuang Information, is leveraging AI technology to enhance its data analysis and information services in the bulk commodity market, aiming to improve operational efficiency and customer experience. Group 1: Company Overview - Zhaochuang Information is a leading provider of bulk commodity information services in China, focusing on data monitoring, price assessment, and industry analysis [7] - The company's main revenue sources include information services (57.19%), digital services (20.98%), exhibition services (12.08%), consulting services (9.74%), and others (0.01%) [7] Group 2: Financial Performance - For the period from January to September 2025, Zhaochuang Information achieved operating revenue of 263 million, representing a year-on-year growth of 19.91%, while net profit attributable to shareholders decreased by 5.93% to 49.52 million [8] - Since its A-share listing, the company has distributed a total of 325 million in dividends [9] Group 3: Technological Advancements - The company has launched an AI platform and automation tools to enhance the production of annual and monthly analysis reports, significantly improving analyst efficiency and customer experience [2] - Zhaochuang Information has developed a commodity price prediction system using advanced machine learning models to assist enterprises in making informed decisions [2] Group 4: Market Activity - As of February 11, the company's stock price decreased by 1.03%, with a trading volume of approximately 84.66 million and a market capitalization of 3.695 billion [1] - The stock has seen a net outflow of 3.45 million from major investors, indicating a lack of strong buying interest [4][5] Group 5: Shareholder Information - As of September 30, the number of shareholders for Zhaochuang Information was 11,800, a decrease of 15.79% from the previous period, while the average number of shares held per shareholder increased by 18.76% to 3,025 shares [8]

Company Fundamentals - The company is expected to incur a loss of between 82.47 million and 123 million yuan in 2025, primarily due to an asset impairment provision of approximately 197 million yuan and a decline in gross profit from integrated sales [3] - Despite recent positive developments such as interest-free loans and litigation mediation, the loss situation remains unchanged, with a price-to-earnings ratio (TTM) of -236.68 times, limiting the stock's upward momentum [3] Market and Technical Analysis - After reaching a limit-up on February 10, the stock experienced a pullback on February 11, closing down 5.74% at 73.35 yuan, attributed to profit-taking, technical overbought conditions, and fundamental pressures [1][2] - The stock's turnover rate was high at 33.22% on February 10, with a trading volume of 1.443 billion yuan, indicating intense short-term trading activity [2] - On February 11, the turnover rate remained at 27.98%, with a trading volume of 1.223 billion yuan, but there was a net outflow of 41.39 million yuan from main funds, suggesting profit realization [2] Industry Sector Overview - The computing power leasing sector saw a slight increase of 0.33% on February 11, while related sectors such as cloud computing and big data generally declined, with the AIGC concept down by 1.85% [4] - Market funds are rotating within popular sectors, and as a small-cap stock with a circulating market value of 4.321 billion yuan, the company is more susceptible to short-term sentiment fluctuations [4] Capital Flow Dynamics - There was a divergence in capital flow, with retail investors actively buying on February 10, while institutional investors net sold 12.3 million yuan and the Shenzhen Stock Connect also saw a net outflow of 4.9 million yuan [5] - This divergence translated into selling pressure the following day, particularly as retail investors favored short-term operations, increasing stock volatility [5]

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. Product Pipeline and Achievements - Junshi Biosciences has a comprehensive capability in the entire industry chain from drug discovery and development to large-scale production and commercialization, aiming to become a global innovative pharmaceutical company based in China [3]. - The company’s core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review. It has also received approvals in multiple countries including the U.S., EU, and Australia [3]. - The company is advancing its proprietary drug tifcemalimab, which is the first anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III clinical trials and several Phase Ib/II studies in various tumor types [3]. Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was a loss of 596 million yuan, although this reflects a 35.72% improvement compared to the previous year [9]. Technological Advancements - The company has deployed an AI translation platform that has replaced over 80% of external translation services for scientific literature, clinical trials, and quality management, enhancing operational efficiency [4]. Market Position - As of February 10, 2023, Junshi Biosciences had a market capitalization of 36.673 billion yuan, with a trading volume of 3.32 billion yuan and a turnover rate of 1.21% [1].

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strategic focus on innovative vaccine development and expanding its product pipeline [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, holds vaccine-related product pipelines, including monkeypox and Zika vaccines, which are currently in preclinical development [2]. - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization [3]. Group 2: Product Pipeline and Achievements - Junshi's core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [3]. - The company has also developed Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III registration clinical trials [3]. - Multiple products are expected to initiate critical registration clinical trials by 2025, showcasing the company's commitment to innovation [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [9]. Group 4: Technological Advancements - Junshi has deployed an AI translation platform that has replaced over 80% of external translation services across various fields, enhancing operational efficiency [4]. - The company has introduced a digital employee, "i Xiao Jun," powered by AI, to support sales with medical information queries and provide IT system support [4].

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Advanced Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. - Junshi Biosciences has a complete industry chain capability from drug discovery and development to large-scale production and commercialization, aiming to become a globally positioned innovative pharmaceutical company [3]. Group 2: Product Pipeline and Innovations - The core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and an additional supplemental NDA under review, showcasing the company's strong market presence [3]. - The company’s self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III registration clinical studies and multiple Phase Ib/II studies in progress [3]. - Junshi Biosciences is exploring early-stage pipelines, with several products expected to initiate critical registration clinical trials by 2025 [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [9]. Group 4: Market Position and Shareholder Information - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, an increase of 15.17% from the previous period, with an average of 21,361 circulating shares per person, a decrease of 12.96% [9]. - The company is part of the pharmaceutical and biotechnology sector, focusing on biopharmaceuticals, including COVID-19 drugs, monkeypox concepts, viral prevention, and precision medicine [9].

Group 1 - The core viewpoint of the news is that Zhen Shitong (002771) has added the "AI Medical" concept due to its investment in Beijing Xinfeng Future Technology Co., Ltd., which focuses on AI applications in healthcare [1] - The company is involved in various other concept sectors including AIGC, Alibaba, high-pressure fast charging, wind power, DeepSeek, liquid cooling servers, charging piles, East Data West Computing, Huawei computing power, computing power leasing, smart healthcare, virtual reality, spatiotemporal big data, trusted computing, industrial interconnection, remote office, Internet of Things, military-civilian integration, artificial intelligence, data centers, and big data [1] - Zhen Shitong's main business segments include multimedia video, artificial intelligence, industrial internet, and new energy charging piles [1] Group 2 - For the first three quarters of 2025, the company reported a main revenue of 215 million yuan, a year-on-year decrease of 11.73% [2] - The net profit attributable to shareholders was -52.77 million yuan, a year-on-year decline of 128.8%, while the non-recurring net profit was -52.82 million yuan, down 107.91% [2] - In the third quarter of 2025, the company achieved a quarterly main revenue of 84.002 million yuan, an increase of 14.82% year-on-year, but the quarterly net profit attributable to shareholders was -15.6964 million yuan, a decrease of 71.01% [2] - The company reported a debt ratio of 31.47%, investment income of -985,700 yuan, financial expenses of 1.7239 million yuan, and a gross profit margin of 15.81% [2]